Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants during their first RSV season; Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see Pharmacology: Pharmacodynamics under Actions).
Beyfortus should be used in accordance with official recommendations.